OVX-033 is under clinical development by Osivax and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OVX-033’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OVX-033 overview
OVX-033 is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is developed based on oligoDOM technology platform. It acts by targeting nucleocapsid. It is administered by intramuscular route.
Osivax overview
Osivax is a clinical-stage biotechnology company that develops vaccines and immunotherapies for infectious and immune system-associated diseases. It offers oligoDOM, a novel proprietary nanoparticles technology designed to trigger superior T-cell responses. The company’s pipeline products include OVX836 which targets the nucleoprotein (NP), a highly conserved internal antigen; OVX033 that targets corona virus nucleocapsid, an internal and invariant antigen. Its other pipeline products comprise Flunivax (A and B strains) for respiratory viruses and HPVAX for human papillomavirus (HPV). The company operates its facilities and research and development center in Australia, France and Belgium. Osivax is headquartered in Paris, Ile-de-France, France.
For a complete picture of OVX-033’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
